Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03560518 · ClinicalTrials.gov registry record · Phase 3
Study of Rapastinel as Monotherapy in Patients With MDD
A Phase 3 study, sponsored by Naurex, Inc, an affiliate of Allergan.
- Terminated
- Registry status
- Phase 3
- Development phase
- 439
- Enrollment target
NCT03560518 is a Phase 3 study that was terminated before completion, run by Naurex, Inc, an affiliate of Allergan. The registered enrollment target is 439 participants.
The verdict
NCT03560518, a Phase 3 study, was terminated before completion, sponsored by Naurex, Inc, an affiliate of Allergan.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 439 participants
- Enrollment target
Study Summary
The study will evaluate the efficacy, safety, and tolerability of 450 milligrams (mg) and 900 milligrams (mg) of Rapastinel, compared to placebo in participants with major depressive disorder (MDD).
Interventions
- DRUG Placebo
- DRUG Rapastinel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 439 participants |
| Start Date | 2018-06-15 |
| Est. Completion | 2019-07-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03560518
The ClinicalTrials.gov registry entry for NCT03560518 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 439 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Naurex, Inc, an affiliate of Allergan, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03560518 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03560518 about?
NCT03560518 is a clinical study titled "Study of Rapastinel as Monotherapy in Patients With MDD". The study will evaluate the efficacy, safety, and tolerability of 450 milligrams (mg) and 900 milligrams (mg) of Rapastinel, compared to placebo in participants with major depressive disorder (MDD).
What is the current status of trial NCT03560518?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 439 participants. The study started on 2018-06-15. Estimated completion is 2019-07-08.
What interventions are being tested in trial NCT03560518?
The interventions under investigation include: Placebo (DRUG), Rapastinel (DRUG).
Who is sponsoring clinical trial NCT03560518?
This trial is sponsored by Naurex, Inc, an affiliate of Allergan, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.